Last reviewed · How we verify

Pneumocystis Carinii Pneumonia Prevention — Treatment Landscape & Competitive Intelligence

Pneumocystis Carinii Pneumonia Prevention (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumocystis Carinii Pneumonia Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pentam PENTAMIDINE Fresenius Kabi Antiprotozoal Muscarinic acetylcholine receptor M4 1984-01-01
Azo Gantanol SULFAMETHOXAZOLE Pfizer Sulfonamide Antimicrobial [EPC] 1973-01-01
Trimethoprim TRIMETHOPRIM Dr Reddys Labs Sa Sulfonamide Antimicrobial [EPC] Dihydrofolate reductase 1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Pneumocystis Carinii Pneumonia Prevention
  2. Dr Reddys Labs Sa · 1 drug in Pneumocystis Carinii Pneumonia Prevention
  3. Fresenius Kabi · 1 drug in Pneumocystis Carinii Pneumonia Prevention
  4. Pfizer · 1 drug in Pneumocystis Carinii Pneumonia Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumocystis Carinii Pneumonia Prevention:

Cite this brief

Drug Landscape (2026). Pneumocystis Carinii Pneumonia Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumocystis-carinii-pneumonia-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing